Advertisements



We are Sorry, This Page doesn't Exist


Allergan"s Vraylar Positive for Bipolar Disease in Phase III

Allergan (AGN) releases positive top-line results from a phase III study on Vraylar for treatment of bipolar I.....»»

Category: worldSource: nytDec 19th, 2017

Arrowhead Pharma Wins in Midstage Hepatitis Study

Arrowhead Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm presented new data from its midstage study for the treatment of hepatitis B infection......»»

Category: blogSource: 247wallstDec 6th, 2017

Alexion (ALXN) Reports Interim Results for Soliris Study

Alexion (ALXN) announced results from an interim analysis of an ongoing phase III REGAIN study of Soliris. The study showed sustained treatment benefits of Soliris treatment for patients with refractory gener.....»»

Category: smallbizSource: nytSep 14th, 2017

Marinus Pharma Wins Big With Mid-Stage Epilepsy Study

Marinus Pharmaceuticals saw its shares make a huge gain to kick off the week after the firm announced top-line results from its mid-stage study in patients with CDKL5 disorder......»»

Category: blogSource: 247wallstSep 11th, 2017

Eli Lilly says late-stage, 12-month study showed its migraine treatment was safe, effective

Eli Lilly & Co. said early Friday that its migraine prevention drug had positive results in a late-stage, 12-month open-label study. The therapy, galcanezumab, showed a positive safety and tolerability profile in patients, the company said, and wa.....»»

Category: topSource: marketwatchSep 8th, 2017

Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results

- Completed patient enrollment in Phase 2 clinical study of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, for treatment of NASH ­-             - Raised $35 million f.....»»

Category: earningsSource: benzingaAug 10th, 2017

Anthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial Results

RESULT, pivotal Phase 3 study of Sollpura began screening patients in the .....»»

Category: earningsSource: benzingaAug 9th, 2017

Paratek Antibiotic Candidate"s Phase III Data Favorable

Paratek Pharmaceuticals, Inc. (PRTK) announced positive results from a phase III study (OASIS-2) comparing its antibiotic candidate omadacycline to Pfizer Inc.'s (PFE) Zyvox for the treatment of acute bacterial.....»»

Category: topSource: zacksJul 18th, 2017

Adamas Pharmaceuticals announces final results from GOCOVRI Phase 3 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 19th, 2018

Scientists Accidentally Created a ‘Mutant Enzyme’ That Could Solve The World’s Plastic Nightmare

A study of bacteria found in a Japanese recycling plant yielded unexpected results. A couple years back, scientists discovered bacteria at a Japanese recycling plant that were breaking .....»»

Category: europeSource: fortuneApr 17th, 2018

Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»

Category: europeSource: fortuneApr 16th, 2018

Pulse Biosciences stock soars to lead premarket gainers after positive study results

Shares of Pulse Biosciences Inc. rocketed 38% in premarket trade Friday, to pace all the premarket gainers, after the company revealed positive results from a study of its treatment for skin lesions. Pulse said late Thursday that .....»»

Category: topSource: marketwatchApr 13th, 2018

Incyte"s stock plunges, Merck shares fall after disappointing study results of melanoma treatment

Shares of Incyte Corp. plunged 19% in premarket trade Friday, and Merck & Co. Inc.'s stock dropped 1.9%, after the companies said an external data monitoring comm.....»»

Category: topSource: marketwatchApr 6th, 2018

Incyte"s stock set for selloff, Merck shares drop after disappointing study results of melanoma treatment

Incyte Corp. and Merck & Co. Inc. said an external data monitoring committee (eDMC) determined that results from a phas.....»»

Category: topSource: marketwatchApr 6th, 2018

Eli Lilly reports positive results in late-stage trial of liver cancer treatment

Eli Lilly and Co. said Wednesday a late-stage trial of a liver cancer treatment met its main goals. The company said patients in a pha.....»»

Category: topSource: marketwatchApr 4th, 2018

Rigel Pharmaceuticals reports results from Phase 2 fostamatinib study in IgAN

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 3rd, 2018

Arrowhead announces dosing in ARO-HBV study for patients with hepatitis B

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 27th, 2018

Merck, Eisai Get Japanese Nod for Lenvima Label Expansion

Merck (MRK) and partner Eisai receive approval in Japan for Lenvima for the first line treatment of patients with unresectable hepatocellular carcinoma (HCC). Merck and Co. MRK along .....»»

Category: personnelSource: nytMar 26th, 2018

Regeneron Eylea Hits 24-Week Primary Endpoint in Study

Regeneron (REGN) announces encouraging top-line results from the phase III study evaluating Eylea injection in moderately severe to severe non-proliferative diabetic retinopathy. Regeneron Pharmaceuticals, Inc. REGN anno.....»»

Category: personnelSource: nytMar 20th, 2018

Arena Pharmaceuticals" stock rockets after positive drug trial results

Shares of Arena Pharmaceuticals Inc. shot up 34% in premarket trade Tuesday, after the drugmaker reported positive results from a phase 2 trial of its treatment for ulcerative colitis. The rally comes a.....»»

Category: topSource: marketwatchMar 20th, 2018